Table 8.

ASSURE patient plasma: apabetalone reduces circulating TNFα targets that correlate with CVD risk in patient plasma

VI process	TNFα target	Protein symbol	Apabetalone versus placebo
			% change	p value
Plaque stability	Stromelysin-1	MMP-3	− 26.8	0.005
Plaque stability	Macrophage metalloelastase	MMP-12	− 24.6	0.003
Inflammatory mediator Plaque stability	Fractalkine	CX3CL1	− 22.0	0.0003
Inflammatory mediator Plaque stability	C-reactive protein	CRP	− 21.3	0.02
Inflammatory mediator Plaque stability	Pappalysin-1	PAPPA	− 14.6	0.02
Inflammatory mediator Plaque stability	Osteoprotegerin	TNFRSF11B	− 14.0	0.003
Inflammatory mediator Plaque stability	Periostin	POSTN	− 13.3	0.01
Inflammatory mediator	Oncostatin-M	OSM	− 13.1	0.01
Atherogenesis Adhesion	Vascular cell adhesion protein 1	VCAM1	− 12.2	0.005
Inflammatory mediator	Toll-like receptor 4:Lymphocyte antigen 96 complex	TLR4 LY96	− 11.2	0.03
Inflammatory mediator	Serum amyloid P-component	APCS	− 10.8	0.001
Inflammatory mediator Plaque stability	Angiopoietin-2	ANGPT2	− 10.2	0.01

Compared to placebo treatment. Placebo group, n = 47; apabetalone treatment group, n = 47